CR20160428A - Pizazinas moduladoras de gpr6 - Google Patents

Pizazinas moduladoras de gpr6

Info

Publication number
CR20160428A
CR20160428A CR20160428A CR20160428A CR20160428A CR 20160428 A CR20160428 A CR 20160428A CR 20160428 A CR20160428 A CR 20160428A CR 20160428 A CR20160428 A CR 20160428A CR 20160428 A CR20160428 A CR 20160428A
Authority
CR
Costa Rica
Prior art keywords
gpr6
pizazinas
modulating
compounds
modulators
Prior art date
Application number
CR20160428A
Other languages
English (en)
Inventor
Stephem Hithcock
Holly Reichard
Maria Hopkins
Holger Monenschein
Jason W Brown
Shota Kikuchi
Mark E Adams
Hukai Shu
Betty Lam
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CR20160428A publication Critical patent/CR20160428A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invención proporciona compuestos de fórmula (I): que son útiles como moduladores de GPR6, composiciones farmacéuticas de los mismos, métodos para el tratamiento de afecciones asociadas con GPR6, procesos para producir los compuestos y productos intermedios de los mismos.
CR20160428A 2014-02-14 2015-02-13 Pizazinas moduladoras de gpr6 CR20160428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461940294P 2014-02-14 2014-02-14
PCT/US2015/015841 WO2015123533A1 (en) 2014-02-14 2015-02-13 Pyrazines modulators of gpr6

Publications (1)

Publication Number Publication Date
CR20160428A true CR20160428A (es) 2017-04-04

Family

ID=52598823

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160428A CR20160428A (es) 2014-02-14 2015-02-13 Pizazinas moduladoras de gpr6

Country Status (24)

Country Link
US (2) US10000468B2 (es)
EP (1) EP3105216B1 (es)
JP (1) JP6484640B2 (es)
KR (1) KR20160122215A (es)
CN (1) CN106103421B (es)
AU (1) AU2015218402B2 (es)
BR (1) BR112016018418A2 (es)
CA (1) CA2939382A1 (es)
CL (1) CL2016002043A1 (es)
CR (1) CR20160428A (es)
DO (1) DOP2016000211A (es)
EA (1) EA033861B1 (es)
EC (1) ECSP16074207A (es)
ES (1) ES2702205T3 (es)
GE (1) GEP20186893B (es)
IL (1) IL247140B (es)
MA (1) MA39337B1 (es)
MX (1) MX369857B (es)
MY (1) MY184366A (es)
PE (1) PE20170245A1 (es)
PH (1) PH12016501613B1 (es)
UA (1) UA117779C2 (es)
WO (1) WO2015123533A1 (es)
ZA (1) ZA201606077B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39337B1 (fr) * 2014-02-14 2019-11-29 Takeda Pharmaceuticals Co Modulateurs de pyrazines de gpr6
EP4108659A1 (en) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
CA3054945A1 (en) 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
JP2004515449A (ja) * 1999-02-26 2004-05-27 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 第６ｇタンパク質共役型受容体の小分子調節物質
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
WO2001060806A2 (en) 2000-02-16 2001-08-23 Neurogen Corporation Substituted arylpyrazines
AU2002319183B2 (en) * 2001-06-01 2007-05-10 F. Hoffmann-La Roche Ag Pyrimidine, triazine and pyrazine derivatives as glutamate receptors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CN101450934B (zh) 2002-03-13 2012-10-10 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
AU2003289330A1 (en) * 2002-12-13 2004-07-09 Kyowa Hakko Kogyo Co., Ltd. Preventives and/or remedies for central diseases
SG145701A1 (en) 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Piperazine derivatives and their use as therapeutic agents
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
AU2005215379A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
DE602005019556D1 (de) 2004-04-13 2010-04-08 Icagen Inc Polycyclische pyrazine als kaliumionenkanal-modulatoren
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
KR20080014775A (ko) 2005-05-13 2008-02-14 렉시컨 파마슈티컬스 인코퍼레이티드 다환 화합물 및 그의 사용 방법
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
US8495335B2 (en) * 2006-06-16 2013-07-23 Raytheon Company Data translation system and method
JP2011524917A (ja) 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド アリールｇｐｒ１１９作動薬およびその使用
DK2563776T3 (en) 2010-04-27 2016-09-19 Calcimedica Inc Relations that modulate intracellular calcium
CA2798325A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
MA34300B1 (fr) * 2010-05-13 2013-06-01 Amgen Inc Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
US10252984B2 (en) * 2011-10-27 2019-04-09 Mayo Foundation For Medical Education And Research Inhibiting G protein coupled receptor 6 kinase polypeptides
US9487526B2 (en) * 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
AU2014340318B2 (en) 2013-10-21 2019-01-17 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
MA39337B1 (fr) * 2014-02-14 2019-11-29 Takeda Pharmaceuticals Co Modulateurs de pyrazines de gpr6

Also Published As

Publication number Publication date
US10273225B2 (en) 2019-04-30
CA2939382A1 (en) 2015-08-20
KR20160122215A (ko) 2016-10-21
BR112016018418A2 (pt) 2017-08-08
EP3105216A1 (en) 2016-12-21
EA201691632A1 (ru) 2017-02-28
CN106103421A (zh) 2016-11-09
GEP20186893B (en) 2018-09-10
WO2015123533A1 (en) 2015-08-20
EP3105216B1 (en) 2018-10-10
US10000468B2 (en) 2018-06-19
CN106103421B (zh) 2019-04-09
UA117779C2 (uk) 2018-09-25
MA39337B1 (fr) 2019-11-29
AU2015218402A1 (en) 2016-09-15
CL2016002043A1 (es) 2017-02-17
US20180258073A1 (en) 2018-09-13
DOP2016000211A (es) 2016-10-16
ES2702205T3 (es) 2019-02-27
PE20170245A1 (es) 2017-03-30
MX369857B (es) 2019-11-25
IL247140A0 (en) 2016-09-29
PH12016501613A1 (en) 2017-02-06
MA39337A1 (fr) 2017-10-31
MY184366A (en) 2021-04-01
JP2017509601A (ja) 2017-04-06
AU2015218402B2 (en) 2019-07-11
MX2016010529A (es) 2016-10-31
ZA201606077B (en) 2018-11-28
IL247140B (en) 2020-02-27
EA033861B1 (ru) 2019-12-03
ECSP16074207A (es) 2017-09-29
PH12016501613B1 (en) 2017-02-06
US20170174659A1 (en) 2017-06-22
JP6484640B2 (ja) 2019-03-13

Similar Documents

Publication Publication Date Title
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
ECSP16073190A (es) Ciclopropilaminas como inhibidores de lsd1
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
ECSP18010535A (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
BR112016028773A2 (pt) processos para preparação de compostos antivirais
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
DOP2018000008A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
ECSP16074207A (es) Pirazinas moduladoras de gpr6
UY36221A (es) Derivados de isoindolinona
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
BR112016028698A2 (pt) preparação de piperidina-4-carbotioamida
BR112017018992A2 (pt) processo de preparação de derivados de fenilisoxazolina substituída